Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) dropped 6.6% during mid-day trading on Tuesday . The company traded as low as $12.94 and last traded at $12.89. Approximately 307,814 shares traded hands during trading, a decline of 30% from the average daily volume of 438,531 shares. The stock had previously closed at $13.80.
Analyst Ratings Changes
A number of equities analysts recently weighed in on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.01 price target on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Wedbush reiterated an "outperform" rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research report on Thursday. Finally, HC Wainwright boosted their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a report on Monday, January 27th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $36.50.
Check Out Our Latest Stock Report on BCAX
Bicara Therapeutics Price Performance
The firm has a 50-day moving average price of $13.04.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). On average, equities research analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.
Institutional Trading of Bicara Therapeutics
Several institutional investors have recently modified their holdings of BCAX. RA Capital Management L.P. acquired a new stake in shares of Bicara Therapeutics in the 3rd quarter worth $177,169,000. Red Tree Management LLC acquired a new position in shares of Bicara Therapeutics in the 4th quarter valued at about $55,230,000. FMR LLC bought a new position in shares of Bicara Therapeutics in the third quarter worth about $57,913,000. Adage Capital Partners GP L.L.C. grew its holdings in shares of Bicara Therapeutics by 171.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company's stock worth $37,893,000 after purchasing an additional 1,375,265 shares during the last quarter. Finally, Braidwell LP boosted its holdings in Bicara Therapeutics by 20.7% during the fourth quarter. Braidwell LP now owns 2,000,659 shares of the company's stock worth $34,851,000 after buying an additional 343,059 shares during the last quarter.
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Read More
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
